Creatine and Motor Skill Acquisition

Effects of Creatine Supplementation on Motor Skill Acquisition and Related Neurophysiology

The investigators will conduct a double-blind, placebo-controlled, repeated measures study of the effects of oral creatine monohydrate supplementation on motor skill acquisition and neurophysiology in young healthy adults. After baseline testing, participants will be randomized to receive creatine supplementation or placebo for seven days. Participants will then complete three days of training on a motor skill task while consuming a maintenance dosage of creatine or placebo. TMS measures of neurophysiology will be assessed at baseline, and pre- and post-skill training on the first and third training days.

Study Overview

• Status: Recruiting
• Conditions: Young Healthy Adults (no Medical Condition/Disease)
• Intervention / Treatment: Dietary supplement: Creatine Monohydrate; Dietary supplement: Maltodextrin Placebo

Detailed Description

Participants: Thirty-six young healthy adults between 18-39 years of age will participate in the study. Participants will follow an omnivore diet given differences in response to creatine supplementation among vegetarians.

Group allocation: Participants will be allocated to study groups (i.e., creatine, placebo) using blocked randomization that stratifies by sex (male, female).

Supplementation and diet: An individual blind to supplement and group allocation will prepare participant study kits. Each study kit will contain daily supplementation bags for the duration of the study, detailed instructions, and a compliance log. Creatine (Creapure® AlzChem Trostberg GmbH, Germany) and placebo (Globe Plus 10 DE Maltodextrin, Univar Canada) will be in powder form and be very similar in color, texture, and appearance. After baseline testing, participants will orally consume creatine or placebo (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days. This 3-g/day dosage has been shown to maintain cellular creatine levels. Adherence with the supplementation protocol will be assessed by the compliance log. Possible adverse events to supplementation (i.e., minor gastrointestinal irritation) will be assessed using adverse event forms. Upon completion of the study, participants will be asked to guess whether creatine or placebo had been administered. Habitual dietary intake will be determined by 3-day food logs completed by participants prior to the study.

Motor skill task: Participants will perform an "intercept and release" task which uses a Microsoft Kinect sensor and open-source software to track 3-dimensional joint movement. Participants will be instructed to "save the world" through control of an on-screen cursor (i.e., spaceship) using movement of their dominant arm to intercept a moving object (an asteroid) as it emerges from the side of a computer screen. After interception of the object, participants will be required to accurately throw the object to hit a target (the sun). The task will progress through 10 stages of increasing difficulty (i.e., increasing object speed, decreasing target size) as skill performance improves. The stages of difficulty are designed to challenge participants, maintain engagement, and prevent plateaus in performance.

Participants will complete one block of 200 movements (i.e., 100 object interceptions, 100 object throws) at the easiest level of difficulty in the baseline testing session. After the initial 7-day creatine supplementation period, three training sessions will be completed on consecutive days. A training session will involve five blocks of 200 movements, for 1,000 skilled arm movements per session (~45 minutes), and a total of 3,000 training movements over the course of the study. A plot of object interception time (y-axis) by successful movement trial (x-axis) across the training period (i.e., days 1-3) will be generated for each participant and fit with an exponential curve. The curve fitting parameter that represents rate of skill acquisition will be extracted for each participant as the primary dependent variable.

Transcranial magnetic stimulation (TMS): Using neuronavigation software, TMS will be applied over the primary motor cortex to elicit motor evoked potentials (MEPs) in the extensor carpii radialis muscle of the dominant arm, a muscle involved in performance of the motor skill task. Using standard procedures, the investigators will collect a battery of TMS measures that provide indices of corticospinal excitability and gamma-aminobutyric acid and glutamate signaling at baseline, and pre- and post-skill training on the first and third days.

• Study Type: Interventional
• Enrollment (Anticipated): 36
• Phase: Early Phase 1

Contacts and Locations

• Study Contact: Name: Darren G Candow, PhD; Phone Number: 306-585-4906; Email: darren.candow@uregina.ca

Study Locations

• Canada
  • Saskatchewan
    • Regina, Saskatchewan, Canada, S4S5N6
      • Recruiting
      • University of Regina
      • Contact: Darren G Candow, PhD; Phone Number: 3065854906; Email: darren.candow@uregina.ca

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 39 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• omnivore diet

Exclusion Criteria:

• pre-existing liver abnormalities
• pre-existing kidney abnormalities
• pre-existing neuromuscular abnormalities
• contraindications to transcranial magnetic stimulation
• consumption of dietary supplements containing creatine within 30 days prior to the start of the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: BASIC_SCIENCE
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Creatine; Participants will orally consume creatine (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days.	Dietary supplement: Creatine Monohydrate; Participants will orally consume creatine (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days. This 3-g/day dosage has been shown to maintain cellular creatine levels.
PLACEBO_COMPARATOR: Placebo; Participants will orally consume maltodextrin placebo (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days.	Dietary supplement: Maltodextrin Placebo; Participants will orally consume maltodextrin placebo (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of change in movement time	Both groups will perform a skill acquisition task that involves moving the dominant upper limb to direct a cursor towards moving targets presented on a computer screen. The task will be practiced over a period of three days. The time required to reach each moving target will be measured (i.e., movement time) with faster times indicating improved performance. The rate of improvement on the task over the three days will be determined.	3 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Single pulse motor evoked potential amplitude	Amplitude of motor evoked potentials measured with electromyography and elicited by single-pulse transcranial magnetic stimulation. Provides a marker of corticospinal excitability.	Days 1 and 3 of training
Short-interval intracortical inhibition motor evoked potential amplitude	Amplitude of motor evoked potentials measured with electromyography and elicited by transcranial magnetic stimulation using paired-pulse short interval intracortical inhibition paradigm.	Days 1 and 3 of training
Intracortical facilitation motor evoked potential amplitude	Amplitude of motor evoked potentials measured with electromyography and elicited by transcranial magnetic stimulation using paired-pulse intracortical facilitation paradigm.	Days 1 and 3 of training

Collaborators and Investigators

• Sponsor: University of Regina
• Investigators: Principal Investigator: Cameron S Mang, PhD, University of Regina

Study record dates

Study Major Dates

• Study Start (ACTUAL): February 10, 2022
• Primary Completion (ANTICIPATED): August 31, 2022
• Study Completion (ANTICIPATED): August 31, 2022

Study Registration Dates

• First Submitted: November 10, 2021
• First Submitted That Met QC Criteria: January 7, 2022
• First Posted (ACTUAL): January 21, 2022

Study Record Updates

• Last Update Posted (ACTUAL): February 24, 2022
• Last Update Submitted That Met QC Criteria: February 22, 2022
• Last Verified: February 1, 2022

More Information

Terms related to this study

• Keywords: motor learning; motor cortex; transcranial magnetic stimulation; creatine; corticospinal excitability
• Other Study ID Numbers: 2021-139

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Will not share individual participant data.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No